Vitiligo in a patient with metastatic melanoma receiving human immunoglobulin G4 monoclonal antibodynivolumab treatment
Nivolumab is an immunotherapy drug developed to increase the ability of the immune system to target and kill cancer cells and is a human immunoglobulin G4 monoclonal antibody blocking programmed cell death-1. Nivolumab is a checkpoint inhibitor that stops a signal that hinders stimulation of the tum...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Galenos Publishing House,
2022-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|